The 60 mg/dL Threshold: What the Science Really Says About LDL Cholesterol and Plaque Formation

For decades, the medical community has debated what constitutes an "optimal" LDL cholesterol level. While current guidelines recommend targets below 100 mg/dL for most people and below 70 mg/dL for high-risk individuals, emerging evidence suggests that atherosclerotic plaque may begin forming at much lower levels than previously thought. A growing body of research points to a critical threshold around 60 mg/dL, below which atherosclerosis appears to be virtually absent, and above which plaque steadily accumulates.

This isn't just theoretical speculation. Multiple landmark studies using advanced imaging techniques have documented this phenomenon in thousands of patients, fundamentally challenging our understanding of what "normal" cholesterol really means.

Infographic Summary Of Why LDL Below 60 Prevents Heart Disease

The PESA Study: A Paradigm Shift in Understanding "Normal" LDL

The Progression of Early Subclinical Atherosclerosis (PESA) study represents one of the most comprehensive investigations into the relationship between LDL cholesterol and plaque formation in apparently healthy individuals. Researchers examined 4,184 asymptomatic middle-aged participants using advanced imaging techniques to detect atherosclerosis in multiple vascular beds—carotid arteries, aorta, iliofemoral arteries, and coronary arteries.

The findings were striking. Among participants with LDL-C levels below 60 mg/dL, researchers found essentially no evidence of atherosclerosis. This suggests that 60 mg/dL may represent a minimum threshold needed for atherosclerotic plaque to develop in the first place.

But perhaps even more revealing was what happened above this threshold. The study documented a linear, dose-dependent relationship between LDL-C levels and atherosclerosis prevalence across the entire spectrum of what we traditionally consider "normal" values. The prevalence of atherosclerosis increased progressively from just 11% in participants with LDL-C between 60-70 mg/dL to a remarkable 64% in those with levels between 150-160 mg/dL.

This wasn't just about whether plaque was present or absent. Higher LDL-C levels correlated with more extensive disease affecting multiple vascular territories. For every 10 mg/dL increase in LDL-C, participants had an 18% higher odds of having multiterritorial atherosclerosis, meaning plaque in multiple locations throughout their arterial system.

What makes these findings particularly important is that they occurred in people who would be considered low-risk by conventional standards. These were individuals without diabetes, without hypertension, without smoking history, and with LDL cholesterol levels that most physicians would consider acceptable or even optimal. Yet half of them already had subclinical atherosclerosis silently developing in their arteries.

The Plaque Progression Studies: When Does Atherosclerosis Stop Growing?

While the PESA study revealed when plaque begins to form, a separate body of research using intravascular ultrasound (IVUS) and coronary angiography has examined a related but distinct question: at what LDL level does existing plaque stop progressing?

An integrated analysis of multiple IVUS studies demonstrated that plaque progression can be halted when LDL-C is lowered to 70-80 mg/dL. However, achieving actual plaque regression—shrinking existing atherosclerotic lesions—requires even lower levels. Analysis of invasive coronary angiography studies showed that coronary lesions do not progress when LDL-C is maintained below 70 mg/dL.

These findings align remarkably well with the PESA data. The threshold for preventing plaque formation (around 60 mg/dL) is very close to the threshold for halting plaque progression (70 mg/dL), suggesting a consistent biological mechanism across the spectrum from primary to secondary prevention.

FOURIER Trial (2017)

This landmark trial randomized 27,564 patients with established ASCVD to evolocumab (a PCSK9 inhibitor) versus placebo on top of statin therapy. The evolocumab group achieved a median LDL-C of 30 mg/dL, the lowest level recorded in a major cardiovascular outcomes trial. Over 2.2 years, evolocumab reduced major cardiovascular events by 15% (HR 0.85) and the key secondary endpoint of cardiovascular death, MI, or stroke by 20% (HR 0.80). Importantly, analyses showed a monotonic, nearly linear relationship between achieved LDL-C and cardiovascular risk continuing below 15 mg/dL, with no inflection point and no safety signal at extremely low levels.

GLAGOV: The Power of Intensive LDL Lowering

The GLAGOV trial provided dramatic evidence of what happens when LDL-C is reduced to very low levels in patients with established coronary disease. This study randomized 968 patients undergoing coronary angiography to receive either high-intensity statin therapy alone (achieving mean LDL-C of 93 mg/dL) or statin plus a PCSK9 inhibitor (achieving mean LDL-C of 37 mg/dL).

The results were unambiguous. The group achieving LDL-C of 37 mg/dL showed actual reduction in both percent atheroma volume and total atheroma volume—meaning their plaques were shrinking. This provided direct evidence that intensive LDL-lowering therapy can not only halt plaque progression but actually reverse existing atherosclerotic disease.

ASTEROID: Plaque Regression with Rosuvastatin

The ASTEROID trial examined 349 patients treated with high-dose rosuvastatin (40 mg daily) for 24 months, using IVUS to measure changes in coronary plaque burden. Treatment lowered LDL-C to a mean of 60.8 mg/dL, right at the critical threshold identified in PESA.

The results were encouraging: two-thirds of patients showed plaque regression, with a mean reduction in percent atheroma volume of 0.98%. This study demonstrated that achieving LDL-C levels around 60 mg/dL with statin therapy alone could produce measurable plaque regression in the majority of patients.

Serial Imaging Studies: The 70% Solution

A prospective computed tomography angiography (CTA) study evaluated the effect of different LDL targets on plaque progression. Patients treated to an LDL-C target below 70 mg/dL showed a 70% greater reduction in plaque progression compared to those with more modest LDL targets.

Additional studies using near-infrared spectroscopy demonstrated that the lipid core burden of coronary plaques, the dangerous cholesterol-rich centers that can rupture and cause heart attacks—decreased only after significant LDL reduction, not with lenient targets. This suggests that achieving very low LDL levels doesn't just slow plaque growth; it actually changes plaque composition in ways that make plaques more stable and less likely to cause acute events.

ODYSSEY OUTCOMES Trial

In nearly 19,000 patients with recent acute coronary syndrome, alirocumab achieved a mean LDL-C of 38 mg/dL and reduced the primary composite endpoint by 15% (absolute risk reduction 1.6 percentage points) over 2.8 years, with a trend toward reduced all-cause mortality.

JUPITER: Primary Prevention with Intensive Therapy

The JUPITER trial examined primary prevention in individuals without established cardiovascular disease but with elevated inflammatory markers. Participants randomized to high-intensity rosuvastatin therapy achieved greater LDL-C reduction and experienced significantly fewer cardiovascular events compared to placebo.

This trial helped establish that intensive LDL-lowering provides benefit even in primary prevention, supporting the concept that earlier and more aggressive intervention may prevent atherosclerosis from developing in the first place.

JUPITER Trial Subanalysis

Among participants randomized to rosuvastatin, those achieving LDL-C below 50 mg/dL had a 65% reduction in the primary cardiovascular endpoint compared to placebo, versus only 24% reduction in those not reaching this threshold. There was also a 46% reduction in all-cause mortality among those achieving LDL-C below 50 mg/dL. 

FOURIER OLE With Very Low LDL Levels

The FOURIER-OLE (Open-Label Extension) study provides the most robust long-term data on achieving very low LDL-C levels, including below 20 mg/dL. In this prespecified analysis of 6,559 patients followed for a median of 5 additional years (total follow-up up to 8.6 years), there was a monotonic relationship between lower achieved LDL-C levels, down to below 20 mg/dL, and lower cardiovascular risk, with no significant safety concerns.

Key Findings from FOURIER-OLE

Among the 6,559 patients with available LDL-C data:

• 24% (1,604 patients) achieved LDL-C below 20 mg/dL

• 40% achieved LDL-C 20 to <40 mg/dL

• 16% achieved LDL-C 40 to <55 mg/dL

• 7% achieved LDL-C 55 to <70 mg/dL

• 12% achieved LDL-C ≥70 mg/dL 

There was a highly significant monotonic relationship between lower achieved LDL-C levels and reduced risk of both the primary endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) and the key secondary endpoint (cardiovascular death, MI, or stroke), with adjusted P-trend <0.0001 for each endpoint, extending down to levels below 20 mg/dL. 

Safety at Ultra-Low LDL-C Levels

Critically, no statistically significant associations existed between lower achieved LDL-C levels and increased risk of safety outcomes, including: 

• Serious adverse events

• New or recurrent cancer

• Cataract-related adverse events

• Hemorrhagic stroke

• New-onset diabetes

• Neurocognitive adverse events

• Muscle-related events

• Non-cardiovascular death

Original FOURIER Trial Data on Ultra-Low LDL-C

In the original FOURIER trial, an exploratory subgroup of 504 patients achieved LDL-C below 10 mg/dL (median 7 mg/dL, IQR 5-9 mg/dL). These patients had adjusted hazard ratios of 0.69 (95% CI 0.49-0.97) for the primary endpoint and 0.59 (95% CI 0.37-0.92) for the key secondary endpoint compared to patients with LDL-C ≥100 mg/dL, representing a 41% relative risk reduction for cardiovascular death, MI, or stroke. Neither serious adverse events nor adverse events leading to drug discontinuation occurred in excess in these ultra-low LDL-C groups.

The following figure from the FOURIER trial demonstrates the sustained LDL-C lowering and cardiovascular benefit with evolocumab:

Meta-Analyses: The Big Picture

A comprehensive meta-analysis of 51 studies involving 9,113 patients examined the effects of various lipid-lowering therapies on plaque regression. The analysis confirmed that lipid-lowering treatments reduced both percent atheroma volume and total atheroma volume, with plaque regression primarily driven by high-intensity statin therapy achieving very low LDL-C levels.

Another meta-analysis of eight trials (1,759 patients) evaluated adding ezetimibe or PCSK9 inhibitors to statin therapy. The results showed that for every 10% decrease in LDL-C, there was approximately 1.0 mm³ regression in total atheroma volume. This dose-response relationship reinforces that when it comes to LDL-lowering and plaque regression, lower is indeed better.

What This Means for Clinical Practice

The 2026 ACC/AHA Dyslipidemia Guidelines have begun to incorporate these findings, now recommending treatment to an LDL-C goal below 70 mg/dL in high-risk primary prevention patients. The guidelines explicitly acknowledge that cumulative lifetime exposure to elevated atherogenic lipoproteins is closely associated with cardiovascular events.

Data from the CARDIA cohort demonstrated that even modest incremental increases in LDL-C over time were associated with significantly increased event rates over 16 years of follow-up. Similarly, the Framingham Heart Study Offspring cohort showed that cumulative exposure to elevated cholesterol in young adulthood increased subsequent coronary heart disease risk in a dose-dependent fashion.

These observations have profound implications. They suggest that:

1. The concept of "normal" LDL cholesterol may need revision. Values between 100-130 mg/dL are statistically normal in Western populations, but they're clearly not biologically optimal if atherosclerosis is silently progressing.

2. Earlier intervention may be warranted. If plaque begins accumulating above 60 mg/dL and cumulative exposure matters, waiting until someone develops clinical disease or reaches a certain age may mean missing a critical window for prevention.

3. Treatment targets should be individualized based on risk. For someone with established disease or very high risk, achieving LDL-C levels of 50-60 mg/dL or even lower may be necessary to achieve plaque regression.

4. Imaging may help guide therapy. Detecting subclinical atherosclerosis in its early stages could identify individuals who would benefit from more intensive LDL-lowering, even if their traditional risk scores suggest otherwise.

The Biological Plausibility

Why would 60 mg/dL represent a threshold for atherosclerosis development? The answer likely relates to the balance between LDL infiltration into the arterial wall and the body's ability to remove it.

At very low LDL-C levels (below 60 mg/dL), the rate of LDL particle entry into the arterial wall may be slow enough that the body's natural clearance mechanisms can keep pace, preventing accumulation. Above this threshold, LDL infiltration exceeds clearance capacity, leading to progressive accumulation, oxidation, and the inflammatory cascade that characterizes atherosclerosis.

This is consistent with observations from populations with genetically low LDL cholesterol and from newborn humans, who typically have LDL-C levels around 30-70 mg/dL and show no evidence of atherosclerosis.

Unanswered Questions and Future Directions

While the evidence for a 60-70 mg/dL threshold is compelling, important questions remain:

- Would population-wide strategies to achieve LDL-C below 60 mg/dL from early adulthood prevent most cardiovascular disease?

- Are there long-term safety concerns with maintaining very low LDL levels for decades?

- How do we balance the benefits of intensive LDL-lowering against medication costs, side effects, and patient preferences?

- Can we identify which individuals are most likely to benefit from very aggressive LDL-lowering?

The upcoming SCOT-HEART 2 trial, which will compare treatment based on identification of subclinical atherosclerosis by coronary CTA with treatment based on standard risk factor scores, may help answer some of these questions.

Conclusion

The convergence of evidence from PESA, JUPITER, ASTEROID, GLAGOV, FOURIER, ODYESSEY, and numerous other trials paints a consistent picture: atherosclerotic plaque formation begins at LDL-C levels above approximately 60 mg/dL, plaque progression can be halted at levels below about 60-70 mg/dL, and plaque regression requires even lower levels, often below 50-60 mg/dL.

This represents a fundamental shift in how we think about cholesterol management. Rather than asking "Is this patient's LDL high enough to treat?" we might instead ask "Is this patient's LDL low enough to prevent disease?"

For clinicians, these findings support a more proactive approach to lipid management, particularly in patients with long life expectancy who will accumulate decades of exposure to atherogenic lipoproteins. For patients, it underscores the importance of knowing your numbers and understanding that "normal" on a lab report doesn't necessarily mean "optimal" for long-term cardiovascular health.

The science is clear: when it comes to LDL cholesterol and atherosclerosis, lower is better, and the threshold for disease development is much lower than most people realize.

References:

Subclinical Atherosclerosis & Plaque Threshold Studies

1. PESA (Progression of Early Subclinical Atherosclerosis) Study – Fernández-Friera L, Fuster V, López-Melgar B, et al. Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. Journal of the American College of Cardiology. 2017;70(24):2979-2991. doi:10.1016/j.jacc.2017.10.024. https://pubmed.ncbi.nlm.nih.gov/29241485

2. PESA Study Overview – Ibanez B, Fernández-Ortiz A, Fernández-Friera L, et al. Progression of Early Subclinical Atherosclerosis (PESA) Study: JACC Focus Seminar 7/8. Journal of the American College of Cardiology. 2021;78(2):156-179. doi:10.1016/j.jacc.2021.05.011. https://pubmed.ncbi.nlm.nih.gov/34238438

Plaque Regression Trials

3. GLAGOV Trial – Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373-2384. doi:10.1001/jama.2016.16951. https://jamanetwork.com/journals/jama/fullarticle/2584184

4. ASTEROID Trial – Referenced in: Slipczuk L, Blankstein R, Bucciarelli-Ducci C, et al. State of the Art: Evaluation and Medical Management of Nonobstructive Coronary Artery Disease in Patients With Chest Pain: A Scientific Statement From the American Heart Association. Circulation. 2025;152(23):e443-e466. doi:10.1161/CIR.0000000000001394. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001394

PCSK9 Inhibitor Cardiovascular Outcomes Trials

5. FOURIER Trial – Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients With Cardiovascular Disease. New England Journal of Medicine. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664. https://www.nejm.org/doi/full/10.1056/NEJMoa1615664

6. FOURIER Trial – Very Low LDL-C Subanalysis – Giugliano RP, Pedersen TR, Park JG, et al. Clinical Efficacy and Safety of Achieving Very Low LDL-cholesterol Concentrations With the PCSK9 Inhibitor Evolocumab: A Prespecified Secondary Analysis of the FOURIER Trial. Lancet. 2017;390(10106):1962-1971. doi:10.1016/S0140-6736(17)32290-0. https://pubmed.ncbi.nlm.nih.gov/28859947

7. FOURIER-OLE (Open-Label Extension) – Gaba P, O'Donoghue ML, Park JG, et al. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023;147(16):1192-1203. doi:10.1161/CIRCULATIONAHA.122.063399. https://pubmed.ncbi.nlm.nih.gov/36779348

8. FOURIER/FOURIER-OLE Stroke Analysis – Monguillon V, Kelly PJ, O'Donoghue ML, et al. Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke. Circulation. 2026;153(2):86-93. doi:10.1161/CIRCULATIONAHA.125.077549. https://pubmed.ncbi.nlm.nih.gov/41178569

9. ODYSSEY OUTCOMES Trial – Referenced in: Michos ED, McEvoy JW, Blumenthal RS. Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease. New England Journal of Medicine. 2019;381(16):1557-1567. doi:10.1056/NEJMra1806939. https://www.nejm.org/doi/full/10.1056/NEJMra1806939

Statin Trials with Very Low LDL-C Outcomes

10. JUPITER Trial – LDL <50 mg/dL Subanalysis – Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dL With Rosuvastatin: The JUPITER Trial. Journal of the American College of Cardiology. 2011;57(16):1666-75. doi:10.1016/j.jacc.2010.09.082. https://pubmed.ncbi.nlm.nih.gov/21492764

Meta-Analyses

11. Very Low LDL-C Meta-Analysis (8 Statin Trials) – Boekholdt SM, Hovingh GK, Mora S, et al. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events: A Meta-Analysis of Statin Trials. Journal of the American College of Cardiology. 2014;64(5):485-94. doi:10.1016/j.jacc.2014.02.615. https://pubmed.ncbi.nlm.nih.gov/25082583

Review Articles & State-of-the-Art Summaries

12. JACC State-of-the-Art Review on Subclinical Atherosclerosis – Ahmadi A, Argulian E, Leipsic J, Newby DE, Narula J. From Subclinical Atherosclerosis to Plaque Progression and Acute Coronary Events: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2019;74(12):1608-1617. doi:10.1016/j.jacc.2019.08.012. https://pubmed.ncbi.nlm.nih.gov/31537271

13. JACC Health Promotion Series on Lipids – Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. Journal of the American College of Cardiology. 2018;72(10):1141-1156. doi:10.1016/j.jacc.2018.06.046. https://pubmed.ncbi.nlm.nih.gov/30165986

14. TIMI Study Group Focus Seminar – Sabatine MS, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8. Journal of the American College of Cardiology. 2021;77(22):2822-2845. doi:10.1016/j.jacc.2021.01.060. https://pubmed.ncbi.nlm.nih.gov/34082913

Clinical Practice Guidelines

15. 2026 ACC/AHA Dyslipidemia Guidelines – Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Journal of the American College of Cardiology. 2026. doi:10.1016/j.jacc.2025.11.016. https://linkinghub.elsevier.com/retrieve/pii/S0735-1097(25)10254-4